Candid Therapeutics, a clinical-stage biotechnology company focused on advancing T-cell engagers for autoimmune and inflammatory diseases, has entered an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ universal multispecific antibody platform WuXiBody. Candid plans to complete IND enabling studies to enable first-in-human studies in the first half of 2026.
Dr. Ken Song, Chairman, President and CEO of Candid, said: “To further solidify our leadership position in T-cell engagers to deplete B cells for treatment of autoimmune and inflammatory diseases, this transaction uniquely positions us with three TCE programs targeting BCMA, CD20, and CD19 in or near clinical development. We are excited to further the advances made by WuXi Biologics and to unlock the full potential of this molecule.”
Dr. Chris Chen, CEO of WuXi Biologics, said: “We’re glad to enable Candid to advance the progress of T-cell engagers through WuXiBodyTM. This collaboration not only showcases the platform’s capabilities in trispecific discovery in addition to its well-validated bispecific discovery, but also reinforces WuXi Biologics’ position as a preferred partner for pioneering next-generation modalities. We look forward to supporting Candid and other global partners in bringing more innovative therapies to benefit patients around the world.”
Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment, and development and sales milestones totaling up to $925 million as well as royalties.
